<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00273468</url>
  </required_header>
  <id_info>
    <org_study_id>392MD/15/C</org_study_id>
    <nct_id>NCT00273468</nct_id>
  </id_info>
  <brief_title>To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)</brief_title>
  <official_title>A Randomised, Active Control, Double-Blind, Double-Dummy, Parallel-Group, Multi-National Study to Assess the Efficacy, Tolerability and Safety of the Granisetron Transdermal Delivery System in Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Administration of Moderately or Highly Emetogenic Multi-Day Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prostrakan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prostrakan Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      To study the safety and effectiveness of a granisetron patch to treat Chemotherapy-Induced
      Nausea and Vomiting (CINV)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients achieving Complete Control of CINV from the first administration until 24 h after the last administration of the moderately or highly emetogenic chemotherapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Times from start of chemotherapy to treatment failure for complete control (CC) and complete response (CR)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from start of chemotherapy to first administration of rescue medication</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from start of chemotherapy to first emetic episode (vomiting/retching)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving CC and CR of CINV during different time periods</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events collected until 14 days after patch removal</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patch adhesion</measure>
  </secondary_outcome>
  <enrollment>630</enrollment>
  <condition>Chemotherapy-Induced Nausea and Vomiting</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granisetron</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be of non-childbearing potential and female patients must have a
             negative pregnancy test at the Screening Visit

          -  Histologically and/or cytologically confirmed cancer with ECOG ≤2

          -  Life expectancy of ≥ 3 months

          -  Assigned to receive the first cycle of a new multi-day chemotherapy regimen including
             the daily administration of cytotoxic agent(s) with the emetogenic potential of level
             3-5 (Hesketh Classification) on 3-5 days

        Exclusion Criteria:

          -  Hypersensitivity to adhesive plasters

          -  Contraindications to 5-HT3 receptor antagonists

          -  Clinically relevant abnormal laboratory values or hepatic, renal, infectious,
             neurological or psychiatric disorders or any other major systemic illness at the
             discretion of the Investigator

          -  Any cause for nausea and vomiting other than CINV

          -  Clinically relevant abnormal ECG parameters

          -  Concomitant radiotherapy of total body, brain or upper abdomen within one week of
             study entry or planned during the study

          -  A patient taking a medication to control the symptoms of a brain tumour, brain
             metastasis or seizure disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2006</study_first_submitted>
  <study_first_submitted_qc>January 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2006</study_first_posted>
  <last_update_submitted>May 2, 2008</last_update_submitted>
  <last_update_submitted_qc>May 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granisetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

